A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3143753 and LY3185643 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2016
At a glance
- Drugs LY 3143753 (Primary) ; LY 3185643 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 23 Sep 2016 Status changed from active, no longer recruiting to completed.
- 09 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
- 15 Jul 2016 Status changed from recruiting to active, no longer recruiting.